“Enjoy glass of wine before eating:” a randomized trial to test the orexigenic effects of this advice in advanced cancer patients

Jatoi, Aminah; Qin, Rui; Satele, Daniel; Dakhil, Shaker R.; Kumar, Pankaj; Johnson, David; Thomas, Sachdev; Stella, Philip J.; Castillo, José María; Li, Min; Fernández-Zapico, Martín E.

doi:10.1007/s00520-016-3190-6

Cited by 7 publications

(21 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Common advice is to drink a glass of wine before meals to increase appetite. Jatoi et al [ 65 ] tested this advice in advanced cancer patients with appetite loss in a randomised controlled trial. Here, 141 patients were randomised to receive either 2 glasses of white wine or an oral nutritional supplement for 3–4 weeks.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Wine: An Aspiring Agent in Promoting Longevity and Preventing Chronic Diseases

et al. 2018

View full text Add to dashboard Cite

Introduction: Moderate wine consumption is a characteristic of the Mediterranean diet. Studies around the world have shown a beneficial effect of moderate alcohol intake, especially wine, on health. This review aims to critically summarise the most recent studies that investigate the beneficial effects of moderate wine intake on human health. Methods: The PubMed database was comprehensively searched to identify trials published from 2013 to 2018 that investigated the association between moderate wine consumption and health. Results: The most recent studies confirm the valuable role of moderate wine consumption, especially red wine, in the prevention and treatment of chronic diseases such as cardiovascular disease, metabolic syndrome, cognitive decline, depression, and cancer. In the meantime, recent studies also highlight the beneficial role of red wine against oxidative stress and in favour of desirable gut bacteria. The beneficial role of red wine has been attributed to its phytochemical compounds, as highlighted by clinical trials, where the effect of red wine has been compared to white wine, non-alcoholic wine, other alcoholic drinks, and water. Conclusions: Moderate wine intake, at 1–2 glasses per day as part of the Mediterranean diet, has been positively associated with human health promotion, disease prevention, and disease prognosis.

show abstract

Section: Resultsmentioning

confidence: 99%

“…There were no statistically significant differences concerning appetite between the two groups. Hence, white wine does not improve appetite or weight in this patient group [ 65 ].…”

Section: Resultsmentioning

confidence: 99%

Wine: An Aspiring Agent in Promoting Longevity and Preventing Chronic Diseases

et al. 2018

View full text Add to dashboard Cite

show abstract

“…After reviewing each study against the eligibility criteria, 48 studies were excluded. Twelve studies were eligible, of which eight were RCTs [6,[16][17][18][19][20][21][22] , three prospective observational studies [23][24][25] and one post hoc analysis study. [26] Twelve studies assessing a total of 1266 patients investigated the effect of nutritional interventions in patients with incurable cancer.…”

Section: Search Results and Selection Of Studiesmentioning

confidence: 99%

“…Four studies examined the effect of oral dietary interventions alone (n=611). Two were RCT's, [18,19] one exploratory prospective observational study, [23] and one post hoc analysis study. [26] Fearon et al (2003) [18] showed that although consumption was below the recommended dose, the intervention group still showed a significant correlation between ONS intake and improved body composition, including weight gain (p<0.001) and an increase in LBM (p<0.036).…”

Section: Oral Dietary Interventionsmentioning

confidence: 99%

“…Only one study, examining nutrition counselling with the emphasis on restricting carbohydrates, reported significant weight loss following intervention. [25] Four studies reported weight stability [16,18,19,21] , although one of those studies, examining nutrition counselling and consumption of an n-3 PUFA enriched ONS alongside chemotherapy, reported an increase in LBM. [21] Of the six studies reporting an improvement in body composition, one study examined nutrition counselling alongside dietary intervention of IAtta [20] , one study examined the effect of an n-3 PUFA enriched ONS [26] and four studies examined multimodal therapies alongside chemotherapy.…”

Section: Body Compositionmentioning

confidence: 99%

See 1 more Smart Citation

A systematic review examining nutrition support interventions in patients with incurable cancer

Blackwood¹,

Hall

Balstad

et al. 2019

Support Care Cancer

View full text Add to dashboard Cite

Recent guidelines by the European Society for Clinical Nutrition and Metabolism (ESPEN) have advocated increased attention to nutritional support in all patients with cancer: however, little is known about the optimal type of nutritional intervention. The aim of this review was to assess the current evidence for nutrition support in patients with incurable cancer. Methods: This review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. EMBASE, Medline and CINAHL were searched from 1990-2018. Evidence was appraised using a modified risk of bias table, based on guidance from the Cochrane Handbook for Systematic Reviews of Interventions. Results: Sixty studies were assessed of which twelve met the eligibility criteria. Eleven studies examined body composition, with six studies reporting improvements in weight. Six studies examined nutritional status with three studies reporting an improvement. Nine studies examined nutritional intake with six showing improvements including significant improvements in dietary and protein intake. Ten studies examined quality of life, with six studies reporting improvements following intervention. The most common nutritional interventions examined were nutrition counselling and dietary supplementation. Conclusions: There is moderate quality evidence to support the need for increased attention to nutrition support in patients with incurable cancer; however, despite some statistically significant results being reported the clinical effects of them were small. Key questions remain as to the optimal timing for these interventions to be implemented (e.g. cachexia stage, illness stage, timing with anticancer therapy) and the most appropriate endpoint measures.

show abstract

Appetite and dietary intake endpoints in cancer cachexia clinical trials: Systematic Review 2 of the cachexia endpoints series

Vagnildhaug,

Balstad,

Ottestad

et al. 2024

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

There is no consensus on the optimal endpoint(s) in cancer cachexia trials. Endpoint variation is an obstacle when comparing interventions and their clinical value. The aim of this systematic review was to summarize and evaluate endpoints used to assess appetite and dietary intake in cancer cachexia clinical trials. A search for studies published from 1 January 1990 until 2 June 2021 was conducted using MEDLINE, Embase and Cochrane Central Register of Controlled Trials. Eligible studies examined cancer cachexia treatment versus a comparator in adults with assessments of appetite and/or dietary intake as study endpoints, a sample size ≥40 and an intervention lasting ≥14 days. Reporting was in line with PRISMA guidance, and a protocol was published in PROSPERO (2022 CRD42022276710). This review is part of a series of systematic reviews examining cachexia endpoints. Of the 5975 articles identified, 116 were eligible for the wider review series and 80 specifically examined endpoints of appetite (65 studies) and/or dietary intake (21 studies). Six trials assessed both appetite and dietary intake. Appetite was the primary outcome in 15 trials and dietary intake in 7 trials. Median sample size was 101 patients (range 40–628). Forty‐nine studies included multiple primary tumour sites, while 31 studies involved single primary tumour sites (15 gastrointestinal, 7 lung, 7 head and neck and 2 female reproductive organs). The most frequently reported appetite endpoints were visual analogue scale (VAS) and numerical rating scale (NRS) (40%). The appetite item from the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30/C15 PAL (38%) and the appetite question from North Central Cancer Treatment Group anorexia questionnaire (17%) were also frequently applied. Of the studies that assessed dietary intake, 13 (62%) used food records (prospective registrations) and 10 (48%) used retrospective methods (24‐h recall or dietary history). For VAS/NRS, a mean change of 1.3 corresponded to Hedge's g of 0.5 and can be considered a moderate change. For food records, a mean change of 231 kcal/day or 11 g of protein/day corresponded to a moderate change. Choice of endpoint in cachexia trials will depend on factors pertinent to the trial to be conducted. Nevertheless, from trials assessed and available literature, NRS or EORTC QLQ C30/C15 PAL seems suitable for appetite assessments. Appetite and dietary intake endpoints are rarely used as primary outcomes in cancer cachexia. Dietary intake assessments were used mainly to monitor compliance and are not validated in cachexia populations. Given the importance to cachexia studies, dietary intake endpoints must be validated before they are used as endpoints in clinical trials.

show abstract

“Enjoy glass of wine before eating:” a randomized trial to test the orexigenic effects of this advice in advanced cancer patients

Abstract: As prescribed in this trial, wine does not improve appetite or weight in advanced cancer patients.

Cited by 7 publications

References 24 publications

Wine: An Aspiring Agent in Promoting Longevity and Preventing Chronic Diseases

Wine: An Aspiring Agent in Promoting Longevity and Preventing Chronic Diseases

A systematic review examining nutrition support interventions in patients with incurable cancer

Appetite and dietary intake endpoints in cancer cachexia clinical trials: Systematic Review 2 of the cachexia endpoints series

Contact Info

Product

Resources

About